Dysregulation of the centrosome duplication cycle has been implicated in tumorigenesis. Our previous work has shown that the human papillomavirus type 16 (HPV-16) E7 oncoprotein rapidly induces aberrant centrosome and centriole duplication in normal human cells. We report here that HPV E7-induced abnormal centriole duplication is specifically abrogated by a small molecule CDK inhibitor, indirubin-3 0 -oxime (IO), but not a kinase-inactive derivative. Importantly, normal centriole duplication was not markedly affected by IO, and the inhibitory effects were observed at concentrations that did not affect the G1/S transition of the cell division cycle. Depletion of CDK2 by siRNA similarly abrogated HPV E7-induced abnormal centrosome duplication and ectopic expression of CDK2 in combination with cyclin E or cyclin A could rescue the inhibitory effect of IO. IO treatment also reduced the steady-state level of aneuploid cells in HPV-16 E7-expressing cell populations. Our results suggest that cyclin/CDK2 activity is critically involved in abnormal centrosome duplication induced by HPV-16 E7 oncoprotein expression, but may be dispensable for normal centrosome duplication and cell cycle progression.
Dysregulation of the centrosome duplication cycle has been implicated in tumorigenesis. Our previous work has shown that the human papillomavirus type 16 (HPV-16) E7 oncoprotein rapidly induces aberrant centrosome and centriole duplication in normal human cells. We report here that HPV E7-induced abnormal centriole duplication is specifically abrogated by a small molecule CDK inhibitor, indirubin-3 0 -oxime (IO), but not a kinase-inactive derivative. Importantly, normal centriole duplication was not markedly affected by IO, and the inhibitory effects were observed at concentrations that did not affect the G1/S transition of the cell division cycle. Depletion of CDK2 by siRNA similarly abrogated HPV E7-induced abnormal centrosome duplication and ectopic expression of CDK2 in combination with cyclin E or cyclin A could rescue the inhibitory effect of IO. IO treatment also reduced the steady-state level of aneuploid cells in HPV-16 E7-expressing cell populations. Our results suggest that cyclin/CDK2 activity is critically involved in abnormal centrosome duplication induced by HPV-16 E7 oncoprotein expression, but may be dispensable for normal centrosome duplication and cell cycle progression.
Introduction
Centrosomes are the major microtubule organizing centers in animal and human cells (Kellogg et al., 1994) .
Even though centrosomes are not strictly required for mitotic spindle formation (Heald et al., 1996; Bobinnec et al., 1998; Khodjakov et al., 2000) , they determine the number of spindle poles and thus spindle polarity in most cell divisions (Hinchcliffe and Sluder, 2001 ). Synchronization of the centrosome duplication and cell division cycles contributes to the preservation of genomic integrity through bipolar mitotic spindle formation and symmetric chromosome segregation (Bornens, 2002) . The presence of abnormal centrosome numbers can predispose cells to multipolar mitoses, which may cause gains and/or losses of whole chromosomes, the most common cytogenetic abnormalities in solid human tumors (Lengauer et al., 1998; Salisbury et al., 1999; Klausner, 2002; Nigg, 2002) . Centrosome abnormalities have been detected in a wide range of cancers (Pihan et al., 1998; Salisbury et al., 1999; Nigg, 2002) . The underlying mechanisms that drive aberrant centrosome duplication in tumor cells, however, are poorly understood. Cyclin E/CDK2 and/or cyclin A/ CDK2 complexes have previously been implicated in regulating centrosome duplication in tight synchrony with the cell division cycle (Hinchcliffe et al., 1999; Lacey et al., 1999; Matsumoto et al., 1999; Meraldi et al., 1999) . The murine protein kinase mMPS1 (Fisk and Winey, 2001 ), B23/nucleophosmin , and CP110 (Chen et al., 2002) may act downstream of CDKs and may serve to license centrosomes for replication. Recent reports, however, provided evidence that cells deficient for CDK2 (Ortega et al., 2003) or cyclin E1/E2 (Geng et al., 2003; Parisi et al., 2003) proliferate largely normal and have no apparent centrosome duplication defects. Similarly, inhibition of CDK2 in a set of colon cancer cell lines using small interfering RNA (siRNA) or antisense strategies did not markedly interfere with cell proliferation or centrosome duplication (Tetsu and McCormick, 2003) . Although compensatory mechanisms by other cyclin/CDK complexes may contribute to cell division and centrosome duplication processes in these model systems, these findings raise the question whether cyclin/ CDK2 activation may also be dispensable for aberrant centrosome duplication triggered by oncogenic stimuli.
We have previously shown that human papillomavirus (HPV)-associated carcinogenesis of the uterine cervix is a particularly useful model to study the impact of oncogenic events on centrosome duplication and chromosomal instability (Duensing and Munger, 2002) . High-risk HPVs are small double-stranded DNA tumor viruses that encode two oncoproteins, E6 and E7 (zur Hausen, 1996) . These oncoproteins target critical growth-regulatory signaling pathways of the infected host cell presumably to establish a cellular milieu that supports viral genome replication (Munger and Howley, 2002) . The high-risk HPV E7 oncoprotein binds and degrades the retinoblastoma (pRB) tumor suppressor protein and the related pRB family members p107 and p130 (Dyson et al., 1989; Boyer et al., 1996; Gonzalez et al., 2001) . In addition, the HPV E7 oncoprotein inactivates the cyclin-dependent kinase (CDK) inhibitors p21
Cip1 (Funk et al., 1997; Jones et al., 1997) and p27 Kip1 (Zerfass-Thome et al., 1996) . This causes unscheduled activation of E2F-mediated gene transcription, upregulation of cyclin E and cyclin A expression, and thus aberrant patterns of CDK2 activity (Zerfass et al., 1995; Martin et al., 1998; Ruesch and Laimins, 1998) . We have shown that HPV-16 E7 rapidly induces centrosome duplication errors, centrosome-related mitotic defects, and aneuploidy in primary human cells (Duensing et al., 2000 (Duensing et al., , 2001 .
In the present study, we analysed whether inhibition of CDKs can interfere with HPV E7-induced centrosome duplication errors. We report that indirubin-3 0 -oxime (IO), a selective and reversible CDK inhibitor (Hoessel et al., 1999) , specifically abrogates HPV-16 E7-induced abnormal centriole and centrosome duplication at concentrations that do not affect normal centrosome duplication or the cell division cycle. Similarly, depletion of cellular CDK2 pools by siRNA also inhibits E7-induced aberrant centriole synthesis. Overexpression of cyclin E/CDK2 and cyclin A/CDK2 complexes triggers abnormal centrosome duplication and rescues the inhibitory effect of IO on HPV E7-induced abnormal centriole duplication. We also demonstrate that IO reduces the steady-state level of aneuploid cells by inhibiting mitotic progression of cells undergoing multipolar cell division. Taken together, our results show that abnormal, oncogene-induced centrosome duplication can be specifically inhibited without affecting normal centrosome duplication and cell proliferation. These findings suggest that normal centrosome duplication differs mechanistically from abnormal centrosome duplication and that these differences may be exploited to selectively target cancer cells.
Results

Small molecule kinase inhibitor indirubin-3
0 -oxime (IO) reduces HPV-16 E7-induced abnormal centriole synthesis without inhibiting S phase
We have previously shown that transient expression of the HPV-16 E7 oncoprotein results in centrosome duplication errors (Duensing et al., 2000) . Since the centrosome duplication status can be accurately assessed by the number of centrioles, we used a human U-2 OS osteosarcoma cell line manipulated to stably express centrin-GFP (Paoletti et al., 1996) . In these cells, individual centrioles are readily discernable by fluorescence microscopy (Duensing et al., 2001) . U-2 OS/ centrin-GFP cells were transiently transfected with HPV-16 E7 and transfected cells were visually selected by mitochondrial expression of DsRED, which was used as a transfection marker (Figure 1a ). U-2 OS cells with more than four centrioles were considered abnormal and, as reported previously (Duensing et al., 2001) , the proportion of such cells was increased in HPV-16 E7-transfected cell populations (Figure 1a , right panel).
To investigate the cell cycle effects of IO in U-2 OS/ centrin-GFP cells, cells were treated with increasing concentrations of IO and the percentage of cells undergoing S phase was assessed using BrdU incorporation (Figure 1b, c) . IO concentrations of 0.1 and 1 mM did not affect the proportion of cells in S phase compared to mock-treated control cells (0.1% DMSO). However, cells treated with 10 mM IO showed a significant reduction of cells in S phase from a mean of 56.3% of cells positive for anti-BrdU staining in controls to 35.9% (1.6-fold, Pp0.05; Figure 1c) .
In order to test whether IO inhibits CDK2 activity in U-2 OS/centrin-GFP cells, we immunoprecipitated CDK2 from whole cell lysates obtained from IO-treated cells and determined kinase activity using a C-terminal fragment of pRB as a substrate. A significant decrease of CDK2 activity compared to mock-treated controls was detected in cells treated with 0.1 mM or higher concentrations of IO (Figure 1d ). Similar to a previously published study (Tetsu and McCormick, 2003) , our findings demonstrate that cell cycle progression remains unaffected in U-2 OS cells despite inhibition of CDK2 activity by IO at concentrations between 0.1 and 1 mM (Figure 1b-d) .
Next, we studied whether IO can interfere with HPV-16 E7-induced abnormal centriole duplication at concentrations that leave cell cycle progression unaffected. U-2 OS/centrin-GFP cells were transiently transfected with expression plasmids encoding HPV-16 E7 or empty vector control (Figure 1e left panel) . At 24 h after transfection, cells were either mock-treated with 0.1% DMSO or treated with 0.1 or 1 mM IO, respectively, for an additional 24 h. Expression of HPV-16 E7 in mocktreated cells was associated with a significant increase of cells with abnormal centriole numbers from 3.9 to 10.2% (2.6-fold, Pp0.001). Compared to mock-treated HPV-16 E7-expressing cells, treatment with 0.1 mM or 1 mM IO for 24 h resulted in a statistically significant reduction of cells with abnormal centriole numbers from 10.2 to 6.1% (1.7-fold; Pp0.05) and 3.8% (2.7-fold; Pp0.001), respectively. Treatment of empty vectortransfected cells with IO did not yield statistically significant changes of the proportion of cells with abnormal centriole numbers compared to controls (Figure 1e , left panel).
To test whether IO affects normal centriole duplication ( Figure 1e , right panel), asynchronously growing U-2 OS/centrin-GFP cells either mock-treated with 0.1% DMSO or treated with 0.1 mM or 1 mM IO for 24 h were assessed for the proportion of cells with duplicated centrioles, that is, three or four centrioles per cell. No statistically significant differences between controls and IO-treated cells populations were observed, indicating that normal centriole duplication is not affected at these IO concentrations ( Figure 1e , right panel).
These findings show that IO can selectively suppress HPV-16 E7-induced abnormal centriole duplication at concentrations that neither affect cell cycle progression nor normal centriole duplication.
Overexpression of CDK2 in combination with cyclin E or A induces abnormal centriole duplication and abrogates the inhibitory effect of IO on HPV-16 E7-induced aberrant centriole amplification
We next set out to analyse whether the ability of IO to inhibit cyclin/CDK2 activity plays a role for the observed abrogation of HPV-16 E7-induced abnormal centriole duplication. In order to test first whether the ability of IO to abrogate abnormal centriole duplication depends on its ability to inhibit protein kinase activity, we treated cells with 1-methyl-indirubin-3 0 -oxime (MeIO), a kinase-inactive analogue of IO (Figure 2a ). N1-methylation of IO, leading to MeIO, prevents the cyclic nitrogen of the lactam ring of IO from donating a hydrogen bond to the peptidyl carbonyl oxygen of CDK2's Glu81, and thus from binding the ATP-binding pocket of the kinase and inhibiting its kinase activity (Hoessel et al., 1999; Davies et al., 2001; Meijer et al., 2003; Polychronopoulos et al., 2004) . U-2 OS/centrin-GFP cells were transiently transfected with empty vector or HPV-16 E7 and treated either with 1 mM IO or 1 mM MeIO for 24 h. As previously observed (Figure 1d ), IO led to a significant reduction of cells with abnormal centriole numbers in HPV-16 E7 transfected cells (3.1-fold, Pp0.05). However, treatment with MeIO had no significant effect on centriole abnormalities (P40.05; Figure 2a ). These results show that the ability of IO to inhibit kinase activity is crucial for its negative effect on HPV-16 E7-induced abnormal centriole duplication. To determine whether the observed effect of IO on E7-induced abnormal centriole duplication may be related to CDK2 inhibition, we used small interfering RNA (siRNA) to deplete CDK2 in U-2 OS/centrin-GFP cells (Figure 2b ). The reduction of CDK2 in vitro kinase activity was confirmed after immunoprecipitation of CDK2 using a C-terminal fragment of the retinoblastoma protein (RB-c) as a substrate (Figure 2c ). We found that the siRNA-induced reduction of CDK2 expression resulted in a significant inhibition of HPV-16 E7-induced abnormal centriole duplication from 11.8% in controls to 6.6% in cells transfected with CDK2-specific siRNA duplexes (1.8-fold, Pp0.005; Figure 2d ). We then tested whether the inhibitory effect of IO on HPV-16 E7-induced abnormal centriole duplication can be overcome by overexpression of CDK2 or its G1/S phase-specific regulatory subunits, cyclins E and A (Figure 2e , f). U-2 OS/centrin-GFP cells were transiently transfected either with empty vector, CDK2, or HPV-16 E7 alone or cotransfected with HPV-16 E7 in combination with cyclin E, cyclin A, cyclin E/CDK2, or cyclin A/ CDK2 (Figure 2e ). After 24 h, cells were either mocktreated with 0.1% DMSO or treated with 1 mM IO for an additional 24 h and then analysed for numerical centriole abnormalities. Expression of CDK2 alone did not result in a significant increase of cells with abnormal centriole numbers (P40.05; Figure 2f ) whereas expression of HPV-16 E7 led to a significant increase from 3.9 to 10.2% (2.6-fold, Pp0.001). A modest increase of cells displaying abnormal centriole numbers was observed when HPV-16 E7 was coexpressed with cyclin E or cyclin A either alone or in combination with CDK2 ( Figure 2f ). As observed before, treatment of HPV-16 E7-transfected U2OS/centrin-GFP cells with 1 mM IO for 24 h resulted in a significant reduction of the proportion of cells with abnormal centriole numbers from 10.2 to 3.8% (2.7-fold; Pp0.001). Expression of cyclin A either alone or in combination with CDK2 abrogated the inhibitory effect of IO and led to a significant increase of cells with abnormal centriole numbers from 3.8 to 14.2% (3.7-fold; Pp0.01) and 15% (3.9-fold; Pp0.005), respectively. Interestingly, expression of cyclin E alone was not able to abrogate the inhibitory activity of IO on HPV-16 E7 induced abnormal centriole duplication. However, coexpression of HPV-16 E7 with cyclin E and CDK2 was able to compensate for the inhibitory effect and led to a significant increase of cells with abnormal centriole numbers from 3.8% in IO-treated HPV-16 E7-expressing cells to 9.5% in IO-treated cells coexpressing HPV-16 E7, cyclin E, and CDK2 (2.6-fold, Pp0.005).
IO reduces numerical centrosome abnormalities in HPV-16 E7-expressing human keratinocytes
To explore the effects of IO on abnormal centrosome duplication and steady-state levels of aneuploidy, we used previously described hTERT-immortalized normal human oral keratinocytes transduced with HPV-16 E7 (TIKs-E7) or with empty vector (TIKs) (Piboonniyom et al., 2003) . TIKs -E7 show an approximately two-to three-fold increase of the proportion of cells with abnormal centrosome numbers, that is, more than two per cell compared to TIKs. Moreover, TIKs-E7 (Piboonniyom et al., 2003) .
Since previous reports have shown that the effects of IO are cell-type specific (Hoessel et al., 1999) , we first determined IO concentrations that do not affect cell cycle progression in TIKs and TIKs-E7. Using BrdU incorporation (Figure 3a, b) , we found that S phase progression was not significantly altered in TIKs at concentrations of 0.01 mM IO (30% positive for BrdU) compared to TIKs treated with 0.1% DMSO alone as solvent control (31.4%; Figure 3b ). In TIKs-E7 cells, concentrations of 0.01 and 0.1 mM IO did not markedly affect the proportion of cells undergoing S phase (25 and 28.9%, respectively, versus 29.3% in mock-treated cells; P40.05). In both TIKs and TIKs-E7, IO concentrations higher than 0.01 or 0.1 mM, respectively, resulted in a reduction of BrdU incorporation (Figure 3b) .
In order to determine the effect of IO on centrosome duplication, TIKs and TIKs-E7 cells were treated with the indicated, non-cell cycle inhibitory concentrations of IO for 24 h and then processed for immunofluorescence microscopy using g-tubulin as a centrosome marker (Stearns et al., 1991) (Figure 3c, d) . A significant reduction in the proportion of cells with abnormal centrosome numbers in the TIKs-E7 population from 11.9% in mock-treated cells to 6.4 and 7% in cells treated with 0.01 or 0.1 mM IO, respectively, was observed (1.9-and 1.7-fold, respectively, both Pp0.005; Figure 3d ).
IO reduces the steady-state level of aneuploid cells in HPV-16 E7-expressing human keratinocytes
We analysed next whether IO can also reduce the steady-state level of aneuploid cells in TIKs-E7 populations (Figure 4a, b) . TIKs and TIKs-E7 cells were treated with 0.01 and 0.1 mM IO, respectively, for 24 h and were then processed for fluorescence in situ hybridization (FISH) analysis for chromosome 11 copy numbers (Figure 4a ). Since the significance of polyploid cells for genomic destabilization is not clearly understood, cells with four or eight copies of chromosome 11 were excluded, however, cells with monosomy for chromosome 11 were included. As reported previously, TIKs-E7 cells showed increased aneuploidy (39.1% in mock-treated TIKs-E7 populations versus 20.5% in mock-treated TIKs). Treatment of TIKs-E7 cells with 0.1 mM IO for 24 h caused a significant reduction of cells with aneusomy of chromosome 11 from 39.1 to 27.1% (1.4-fold, Pp0.05; Figure 4b ). To investigate potential mechanisms that may contribute to the observed rapid reduction of aneuploid cells, we studied mitoses in TIKs and TIKs-E7 cells (Figure 4c, d) . Asynchronously growing cells were either mock-treated with 0.1% DMSO or treated with 0.01 or 0.1 mM IO for 24 h. Cells were then stained for g-tubulin and analysed for the overall proportion of cells in metaphase or ana-/telophase, and the proportion of cells undergoing multipolar metaphase or ana-/telophase, respectively (Figure 4c, d) . Although the overall proportion of cells in metaphase was found to be consistently higher than the proportion of cells in ana-/ telophase, no significant overall reduction of either metaphase or ana-/telophase cells was found in IOtreated populations (Figure 4c ). When analysing only cells exhibiting evidence of multipolar cell division (Figure 4d ), we found that in TIKs the proportion of cells in metaphase or ana-/telophase, respectively, was not altered upon treatment with IO. In contrast, mocktreated TIKs-E7 cells showed an increased proportion of multipolar ana-/telophase cells, but such cells were absent in TIKS-E7 populations treated with either 0.01 or 0.1 mM IO (Figure 4d) .
In summary, these findings demonstrate that IO can significantly reduce the steady-state level of aneuploid cells in TIKs-E7 populations. Mechanistically, the absence of multipolar ana-/telophase cells in IO-treated TIKs-E7 cells may indicate that IO can inhibit progression through mitosis of cells with ectopic expression of HPV E7 and abnormal numbers of spindle poles.
Discussion
The present study was designed to test whether normal and abnormal centrosome duplication have different requirements for active cyclin/CDK complexes. We show that abnormal centrosome duplication induced by the HPV-16 E7 oncoprotein is selectively inhibited by 0 -oxime (IO), a small-molecule CDK inhibitor (Hoessel et al., 1999) . Importantly, IO did not affect cell cycle progression or normal centriole duplication at concentrations that suppressed abnormal centrosome duplication. Since IO treatment resulted in inhibition of CDK2 activity, these findings suggest that, consistent with recent reports (Geng et al., 2003; Ortega et al., 2003; Parisi et al., 2003; Tetsu and McCormick, 2003) , normal cell cycle progression and centrosome duplication can proceed despite impaired CDK2 activity. However, our findings also show that abnormal centrosome duplication induced by HPV-16 E7 depends on CDK2 activity since depletion of CDK2 protein by siRNA results in decreased numerical centriole abnormalities (Figure 2d) . Moreover, overexpression of either cyclin A alone or cyclin E or cyclin A in combination with CDK2 induced abnormal centriole duplication and could override the inhibitory effect of IO on HPV-16 E7-induced centrosome duplication errors (Figure 2f ). These results suggest that CDK2 activity may be critically involved in inducing multiple rounds of centrosome duplication (Hinchcliffe et al., 1999; Lacey et al., 1999; Matsumoto et al., 1999; Meraldi et al., 1999) whereas other protein kinases may drive the initial round of duplication as suggested by previous work (Matsumoto and Maller, 2002) . Clearly, the inhibitory activity of IO on aberrant centrosome duplication depends on its ability to suppress kinase activity since MeIO, a kinase-inactive form of IO, did not affect HPV E7-induced centriole duplication errors (Figure 2a) . In addition to CDK2, IO can also inhibit CDK1, CDK5, and GSK-3b activity (Hoessel et al., 1999; Damiens et al., 2001; Leclerc et al., 2001; Marko et al., 2001 ) and may upregulate p27 Kip1 transcription through the aryl hydrocarbon receptor (Knockaert et al., 2004) . Evidence that these additional effects of IO may not significantly contribute to the inhibition of HPV E7-induced centrosome abnormalities comes from previous experiments by our group and others. We have previously shown that roscovitine, which effectively inhibits cyclin/CDK2 complexes but does not affect GSK-3b activity (Meijer et al., 1997) , also abrogates HPV E7 oncoproteininduced abnormal centrosome duplication (Duensing et al., 2000) . Moreover, dominant-negative CDK1 does not interfere with centrosome duplication (Meraldi et al., 1999) . CDK5 is active primarily in postmitotic neurons (Tsai et al., 1994) and is therefore similarly unlikely to contribute to the observed inhibitory effects of IO in osteosarcoma cells or primary keratinocytes. Since MeIO is an even more potent activator of AhR and inducer of p27 Kip1 than IO (Knockaert et al., 2004) , but is unable to abrogate E7-induced centrosome duplication errors in our experiments (Figure 2a) , we conclude that AhR-induced p27
Kip1 upregulation does not contribute to the ability of IO to block abnormal centrosomal duplication in a major way. Consistent with this notion, immunoblot analysis of U-2 OS/centrin-GFP cells treated with IO did not reveal a major increase of p27 Kip1 levels (data not shown). In combination with the CDK2 knockdown results (Figure 2c ), these findings suggest that CDK2 inhibition importantly contributes to the ability of IO to suppress abnormal centrosome duplication. Nevertheless, our data do not completely rule out a contribution of IO-induced AhR-dependent effects or inhibition of other protein kinases on IO-mediated inhibition of abnormal centrosome duplication.
It has been described previously that the centrosome duplication and cell division cycles can under certain conditions become uncoupled (Kuriyama et al., 1986; Balczon et al., 1995) . Our findings support the model that oncogenic stimuli such as expression of HPV-16 E7 can rapidly uncouple cell division cycle and centrosome duplication cycle through dysregulation of CDK2 activity (Duensing and Munger, 2002) . The selective abrogation of abnormal centrosome duplication by IO may be due to the fact that centrosome duplication may be more susceptible to IO inhibition as a consequence of their cytoplasmic localization. Alternatively, the level of protein kinase activity necessary to trigger abnormal daughter centriole synthesis and/or to overcome the intrinsic block to re-replicate (Wong and Stearns, 2003) may be lower compared to DNA replication. In the context of cell cycle-mediated control of centrosome duplication, our results are consistent with previous findings that cyclin A tends to be more active with respect to the induction of abnormal centrosome numbers in mammalian cells (Meraldi et al., 1999) . Moreover, our results are also in agreement with other reports that overexpression of cyclin E alone does not result in abnormal centrosome numbers (Spruck et al., 1999; Mussman et al., 2000) . Notably, however, coexpression of cyclin E in combination with CDK2 gives rise to abnormal centrosome numbers (Figure 2e) . It is not known in detail why cyclin E requires coexpression with CDK2 in order to promote abnormal centrosome duplication whereas cyclin A alone is sufficient to induce such abnormalities, which are only moderately enhanced by CDK2 coexpression. This finding, however, may at least in part explain why cells deficient for cyclin E have no apparent centrosome duplication defect (Geng et al., 2003) . Cyclin E is an unstable protein that is rapidly degraded by the ubiquitin/proteasome machinery, whereas cyclin A remains stable throughout S phase (Pines and Hunter, 1990; Hunt et al., 1992) . Although no gross differences in protein steady-state levels were detected by immunoblotting, small differences of cyclin/CDK2 activity at the centrosome, which may not be detected by the methods used here could account for the observed differences. Cyclin E/CDK2 and cyclin A/CDK2 complexes may also have distinct functions for the centrosome duplication cycle. Cyclin E/CDK2 activity is high at the G1/S transition of the cell division cycle and may therefore contribute to the initiation or 'licensing' of centriole duplication. Daughter centriole synthesis, however, occurs during S phase when cyclin A/CDK2 is predominantly active. Once centrioles are 'licensed' for duplication and remain in this state for a prolonged period of time, abnormal patterns of cyclin A/CDK2 may promote aberrant daughter centriole synthesis.
The importance of CDK2 activity for cancer cell growth has recently been challenged based on observations that depletion of the CDK2 protein or its regulatory subunit cyclin E did not significantly interfere cell cycle progression and centrosome duplication of a set of colon cancer cell lines (Geng et al., 2003; Ortega et al., 2003; Parisi et al., 2003; Tetsu and McCormick, 2003) . Our results agree with these findings since normal cell cycle progression and centrosome duplication were not affected by low concentrations of IO. However, we clearly show that abnormal centrosome duplication can be triggered by aberrant cyclin/CDK2 activity and that low concentrations of IO effectively blocks centrosome overduplication but not normal centrosome duplication. Additional support for the notion that CDK inhibitors may indeed be suitable for antineoplastic therapy comes from our observation that IO reduces the steady-state level of aneuploid cells, presumably by interfering with metaphase to anaphase transition of cells with multiple spindle poles (Figure 4d ).
In summary, our results suggest that CDK2 activity is critically involved in abnormal centrosome duplication triggered by oncogenic stimuli such as the HPV-16 E7 oncoprotein, but is dispensable for normal centrosome duplication and cell cycle progression. Our findings therefore strongly suggest that small molecule protein kinase inhibitors will prove to be useful to selectively target cancer cells while leaving normal cells relatively unaffected.
Material and methods
Cell culture, retroviral infections, and cell transfections
The human U-2 OS osteosarcoma cells line stably expressing a centrin-GPF-encoding construct (kindly provided by Michel Bornens, Institut Curie, Paris) was maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum, 50 U/ml penicillin, and 50 mg/ml streptomycin (Invitrogen, Grand Island, NY, USA). U-2 OS/centrin-GFP cells were transiently transfected with pCMVneo-based plasmids (Baker et al., 1990) as indicated using calcium phosphate coprecipitation (Chen and Okayama, 1987) . Plasmids encoding CDK2, cyclin E, or cyclin A were kindly provided by Philip W Hinds (Harvard Medical School). Cells were cotransfected with a DsREDencoding plasmid (BD Biosciences Clontech, Palo Alto, CA, USA) to mark transfected cells.
hTERT-immortalized human keratinocytes expressing empty pBABE (TIKs) or HPV-16 E7 (TIKs-E7) have been described previously (Piboonniyom et al., 2003) and were generated from primary oral keratinocyte populations by retroviral transduction of the hTERT gene cloned in a pBABE-hygromycin vector (kindly provided by Robert A Weinberg, Massachusetts Institute of Technology, Cambridge, MA, USA). Cells were subsequently infected with pBABE-puromycinbased retroviral constructs encoding the HPV-16 E7 oncoprotein or empty pBABE vector. TIKs were maintained in keratinocyte serum-free medium (Keratinocyte-SFM; Life Technologies, Carlsbad, CA, USA) supplemented with epidermal growth factor, bovine pituitary extract, 50 U/ml penicillin, 50 mg/ml streptomycin (Life Technologies), 0.1 mg/ml gentamicin (Life Technologies), and 0.5 mg/ml fungizone (Gemini, Calabasas, CA, USA).
Inhibitor treatment and in vitro kinase assay IO and MeIO were synthesized as described elsewhere (Hoessel et al., 1999; Meijer et al., 2003; Polychronopoulos et al., 2004) . Cells were treated with IO dissolved in dimethyl sulfoxide (DMSO) for 24 h at the indicated concentrations. MeIO was applied under the same conditions. In all experiments, cells treated with 0.1% DMSO were included as solvent control.
CDK2 kinase assays were performed with 250 mg of U-2 OS/centrin-GFP protein lysate. Immunoprecipitations using polyclonal rabbit anti-CDK antibodies (M2, Santa Cruz, Santa Cruz, CA, USA) were performed for 2 h at 41C. Immunocomplexes were bound to protein ASepharose overnight and washed three times in lysis buffer (150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 0.5% NP-40, 0.5 mM PMSF, 1 mg/ml aprotinin and leupeptin, 2 mM NaF, and 0.5 mM Na-vanadate) and twice in kinase buffer (20 mM MgCl 2 , 50 mM Tris-HCl at pH 7.4). Samples were then resuspended in 20 ml of kinase buffer containing 100 mM ATP (Amersham Biosciences, Piscataway, NJ, USA) in the presence of 2 mg of recombinant C-terminal fragment of the retinoblastoma protein comprising amino acids 773-928 (Upstate, Lake Placid, NY, USA). Phosphorylation of RB-c was determined using a phospho-specific antibody against serine 807/811 (Cell Signaling). Total RB-c was measured using an antibody recognizing the C-terminus of pRB (clone 4H1; Cell Signaling). The reduction of RB-c phosphorylation or CDK expression was determined by measuring the signal intensity of bands using ImageJ software and normalization against controls.
Immunological methods
Immunoblot analysis was performed as described previously (Jones et al., 1997) . Antibodies used were directed against HPV-16 E7 (ED17, Santa Cruz), pRB (Ab-5, Oncogene Science, San Diego, CA, USA), CDK2 (M2, Santa Cruz), cyclin E (HE12, Santa Cruz), cyclin A (BF683, Santa Cruz), and actin (Chemicon, Temecula, CA, USA).
For immunofluorescence analysis, cells were grown on coverslips, fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) and permeabilized with 1% Triton X-100 in PBS for 15 min each at room temperature. Cells were then blocked with 10% normal donkey serum (Jackson Immunoresearch, West Grove, PA, USA) and incubated with a mouse monoclonal anti-g-tubulin antibody (GTU-88, Sigma, St Louis, MO, USA) at a 1 : 1000 dilution overnight at 41C followed by a donkey anti-mouse rhodamine red-conjugated secondary antibody (Jackson Immunoresearch) at a 1 : 100 dilution in PBS for at least 1 h at 371C. Cells were finally washed in PBS, counterstained with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI; Vector, Burlingame, CA, USA), and analysed using a Leica DMLB epifluorescence microscope equipped with a Sony DKC5000 camera system. Pictures were transferred to Adobe's Photoshop for printout.
RNA interference (siRNA)
Synthetic RNA duplexes were used to reduce cellular CDK2 expression (Elbashir et al., 2001) . Oligonucleotides targeting CDK2 (5 0 -ACUUGGACCCAAAG-CAGGU-3 0 ) and duplexes with inverted sequence (5 0 -ACCUGCUUUGGGUCCAAGU-3 0 ) were obtained commercially (Ambion, Austin, TX, USA). For each experiment, U-2 OS/centrin-GFP cells were grown on coverslips in 60 mm plates with 2 ml DMEM free of antibiotics. Cells were transfected with 12 ml of 20 mM annealed RNA duplexes using Oligofectamine (Life Technologies) transfection reagent. After 24 h, cells were cotransfected with 2 mg of pCMV-HPV-16 E7 or empty vector control and 0.2 mg DsRED-encoding plasmid using Fugene 6 (Life Technologies) and processed for fluorescence microscopy after an additional 48 h.
5-Bromo-2
0 -deoxy-uridine (BrdU) labeling
Immunofluorescence detection of 5-Bromo-2 0 -deoxyuridine (BrdU) incorporation into cellular DNA was performed in order to determine the fraction of cells undergoing S phase according to the manufacturer's protocol (Roche Molecular Biochemicals, Indianapolis, IN, USA).
Fluorescence in situ hybridization
For interphase fluorescence in situ hybridization analysis, a Spectrum Green-labeled chromosome 11 a-satellite probe (D11Z1) was used according to manufacturer's protocol (Vysis, Downers Grove, IL, USA).
Statistical analysis
At least three independent experiments with at least 100 cells counted each were performed unless indicated otherwise. Mean and standard error are given. Statistical significance was assessed using the two-tailed Student's t-test for independent samples. P-values p0.05 were considered statistically significant. Abbreviations AhR, aryl hydrocarbon receptor; ATP, adenosine 5 0 -triphosphate; CDK, cyclin-dependent kinase; DTT, dithiothreitol; GSK-3b, glycogen synthase kinase-3b; HPV, human papillomavirus; IO, indirubin-3 0 -oxime; MeIO, 1-methyl-indirubin-3 0 -oxime; PMSF, phenylmethylsulfonyl fluoride; pRB, retinoblastoma tumor suppressor protein; siRNA, small interfering RNA.
